Literature DB >> 9247102

Expression of c-Myc, TGF-alpha and EGF-receptor in sporadic medullary thyroid carcinoma.

W Wang1, H E Johansson, U I Bergholm, K M Westermark, L E Grimelius.   

Abstract

In 20 patients with sporadic medullary thyroid carcinoma (MTC), immuno-histochemistry was used to localize the expression of the c-Myc oncoprotein, transforming growth factor alpha (TGF-alpha) and epidermal growth factor receptor (EGFR) and these three markers were analysed regarding their relation to histopathological and histochemical variables of the tumours. The detection rates of c-Myc, TGF-alpha and EGFR were 90%, 90% and 95% respectively. Concomitant demonstration of the markers was reflected in significant associations (correlation factor between TGF-alpha and EGFR was 0.93, p < 0.001). The markers were almost invariably located within the cytoplasm, which might suggest their crucial role in growth regulation and cell differentiation; this seems especially true of TGF-alpha and EGFR. The different markers showed no relation to either histopathological or histochemical variables (tumour behaviour, tumour size, tumour cell type). The prominent co-expression of c-Myc, TGF-alpha and EGFR proteins indicates that in MTC these factors might be of importance for tumour cell proliferation via autocrine growth stimulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247102     DOI: 10.3109/02841869709001288

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

Review 1.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

2.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Authors:  Bruce G Robinson; Luis Paz-Ares; Annetta Krebs; James Vasselli; Robert Haddad
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

3.  A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839).

Authors:  M Höpfner; A P Sutter; B Gerst; M Zeitz; H Scherübl
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.